MicroVue SC5b-9 Plus EIA Kit *
* FOR RESEARCH USE ONLY IN THE UNITED STATES. NOT FOR USE IN DIAGNOSTIC PROCEDURES
An enzyme immunoassay for the quantitation of SC5b-9 complex present in human serum or plasma.
A029 (IVD, CE Mark for EU only)
| 107 Min
| 96 Wells/Plate
| Serum and Plasma |
Summary And Explanation
The MicroVue SC5b 9 Plus Enzyme Immunoassay measures the amount of the SC5b 9 complex present in human plasma or serum specimens.
The Terminal Complement Complex (TCC, SC5b-9) is generated by the assembly of C5 through C9 as a consequence of activation of the complement system by either the classical, lectin or alternative pathway. The membrane attack complex (MAC), a form of TCC, is a stable complex that mediates the irreversible target cell membrane damage associated with complement activation.1-4 Complexes formed in the absence of a target membrane bind to naturally occurring regulatory serum proteins, e.g. the S protein,5-7 at the C5b 7 stage of assembly forming, soluble, non-lytic TCC.1,5
The MicroVue SC5b 9 Plus Enzyme Immunoassay measures the concentration of TCC thereby giving an indication of the status of the terminal complement pathway in the specimen. It uses a monoclonal antibody to the C9 ring of TCC to capture the complex. The trapped TCC is subsequently detected with HRP-conjugated antibodies that bind to antigens of the SC5b 9 complex. This test, which provides a rapid, highly specific and quantitative procedure for measuring TCC levels, is designed for investigations studying the role or status of terminal complement pathway activation in numerous research settings.8-12
- Müller-Eberhard, H.J., The Membrane Attack Complex, Springer Seminars in Immunopathology, Vol. 7, p.93, 1984.
- Lachmann, P.J. and Thompson, R.A., Reactive lysis: The complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J. Exp. Med., Vol. 131, p.643, 1970.
- Götze, O., and Müller-Eberhard, H.J., Lysis of erythrocytes by complement in the absence of antibody. J. Exp. Med., Vol. 132, p.898, 1970.
- Kolb, W.P., Haxby, J.A., Arroyave, C.M., and Müller-Eberhard, H .J., Molecular analysis of the membrane attack mechanism of complement. J. Exp. Med., Vol. 135, p.549, 1972.
- Kolb, W.P., and Müller-Eberhard, H.J., The membrane attack mechanism of complement. Isolation and subunit composition of the C5b-9 complex, J. Exp. Med., Vol. 141, p.724, 1975.
- Podack, E.R., Kolb, W.P., and Müller-Eberhard, H.J., The C5b-6 complex: formation, isolation, and inhibition of its activity by lipoprotein and the S-protein of human serum. J. Immunol., Vol. 120, p.1841, 1978.
- Podack, E.R. and Müller-Eberhard, H.J., Isolation of human S-protein, of an inhibitor of the membrane attack complex of complement. J. Biol. Chem., Vol. 254, p.9808, 1979.
- Sefton, M.V., et al "Using ELISA to evaluate complement activation by reference biomaterials". J. Mat. Sci, 5:622-627, 1994.
- Mold, C. Tamerius, J.D., et al "Complement activation during painful crisis in sickle cell anemia" Clinical Immunology and Immunopathology, 70:3,314-320 (1995).
- Rinder, C. et al, "Blockade of C5a and SC5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation.: J. Clin.Invest, 96:3, 1564-1572 (1995).
- Rollins, S. et al "Monoclonal Antibodies directed against C5 and C8 block complement mediated damage of xenogenic cells and organs." Transplantation 60:11, 1284-1292 (1995).
- Yeh, G. et al "A soluble chimeric complement inhibitory protein that posses both DAF and Factor I cofactor activities." J. Immuno.158.2872-2881 (1997).